Vanesa GarcÃ-a-BarberÃ¡n

List of Publications by Year
in descending order

31 papers	1,388 citations	623734 14 h-index	580821 25 g-index
32 all docs	32 docs citations	32 times ranked	3361 citing authors

#	Article	IF	Citations
1	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
2	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
3	Circulating biomarkers for early detection and clinical management of colorectal cancer. Molecular Aspects of Medicine, 2019, 69, 107-122.	6.4	214
4	Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	1.6	90
5	Differential distribution and enrichment of non-coding RNAs in exosomes from normal and Cancer-associated fibroblasts in colorectal cancer. Molecular Cancer, 2018, 17, 114.	19.2	61
6	Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer, 2017, 17, 210.	2.6	59
7	Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients. Molecular Cancer, 2021, 20, 73.	19.2	44
8	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
9	Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Scientific Reports, 2019, 9, 8976.	3.3	34
10	Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report. Journal of Medical Genetics, 2019, 56, 453-460.	3.2	30
11	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
12	A Snapshot of The Tumor Microenvironment in Colorectal Cancer: The Liquid Biopsy. International Journal of Molecular Sciences, 2019, 20, 6016.	4.1	27
13	Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition. PLoS ONE, 2018, 13, e0203885.	2.5	24
14	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
15	Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer. Cancers, 2021, 13, 833.	3.7	11
16	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
17	Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome. PLoS ONE, 2017, 12, e0187312.	2.5	10
18	Contribution of New Adenomatous Polyposis Predisposition Genes in an Unexplained Attenuated Spanish Cohort by Multigene Panel Testing. Scientific Reports, 2019, 9, 9814.	3.3	9

#	Article	IF	Citations
19	Detection of IDH1 Mutations in Plasma Using BEAMing Technology in Patients with Gliomas. Cancers, 2022, 14, 2891.	3.7	8
20	BRIP1, a Gene Potentially Implicated in Familial Colorectal Cancer Type X. Cancer Prevention Research, 2021, 14, 185-194.	1.5	7
21	Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer. Cancers, 2021, 13, 4118.	3.7	7
22	A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families. Familial Cancer, 2017, 16, 567-575.	1.9	5
23	Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay.. Journal of Clinical Oncology, 2018, 36, 592-592.	1.6	2
24	Plasma PD-L1 levels according to histologic grade and IDH status in patients with gliomas.. Journal of Clinical Oncology, 2020, 38, 69-69.	1.6	2
25	Mutational profile of dysplastic lesions evolving to laryngeal cancer.. Journal of Clinical Oncology, 2019, 37, e17551-e17551.	1.6	1
26	Noninvasive EGFR testing in plasma circulating free DNA (cfDNA) by a new diagnostic method to detect point mutations, deletions and insertions associated to non small cell lung cancer: CLART CMA EGFR LB.. Journal of Clinical Oncology, 2017, 35, e20008-e20008.	1.6	0
27	RAS analysis of circulating tumor cells from advanced colorectal cancer using BEAMing technology.. Journal of Clinical Oncology, 2019, 37, e15151-e15151.	1.6	0
28	Monitoring of PIK3CA and ESR1 mutations in circulating tumor DNA as predictive and prognostic biomarkers in patients with endocrine-resistant ER+/HER2- advanced breast cancer.. Journal of Clinical Oncology, 2020, 38, e13045-e13045.	1.6	0
29	Comparison of circulating tumor cells and cell-free DNA in the molecular characterization of patients with head and neck cancer.. Journal of Clinical Oncology, 2020, 38, e18521-e18521.	1.6	0
30	Abstract P2-01-18: Orthogonal assessment of PIK3CA and ESR1 mutation detection in longitudinal cfDNA samples from endocrine-resistant HR+/HER2- advanced breast cancer patients using dPCR and NGS-based SafeSEQ technology. Cancer Research, 2022, 82, P2-01-18-P2-01-18.	0.9	0
31	Abstract P3-05-06: Genome-wide DNA methylation analysis identifies novel biomarkers associated with risk of relapse beyond oncotype DX recurrence-score risk assessment within HR+/HER2- early-stage breast cancer patients. Cancer Research, 2022, 82, P3-05-06-P3-05-06.	0.9	0